News

Toronto, February 1, 2021 — GoodCap Wellness Inc. (“GoodCap” or the “Company”), a life sciences company developing psilocybin-based therapeutics focused on the impact of inflammation on mental health, today announced appointment of a new Board of Directors including industry experts in pharmaceutical drug development, biotechnology, brand creation, and business development, with track records in building successful companies and bringing drug

Toronto, October 1, 2020 — Sansero Life Sciences, a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and how low-dose psilocybin affects mental health conditions such as

Toronto, September 3, 2020 — CannaGlobal Canada Co. Inc., Sansero Life Sciences Inc., and Rise Wellness this week announced the completion of their amalgamation to form CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Sansero Life Sciences is developing psilocybin-based pharmaceutical products to treat mental health conditions, and Rise Wellness has deep

Toronto, July 6, 2020 — CannaGlobal, Sansero Life Sciences, and Rise Wellness today announced the creation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Leveraging an internationally renowned team with a track record of success, the company will be ideally positioned in the evolving psychedelics industry. Lorne